glp 1 agonist parkinson Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum — Mechanisms, evidence, and future directions Frontiers | Glucagon-like peptide 1

Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems

Results of a study indicated that chemotherapeutic agents-induced oxidative stress caused TRPA1 activation instead of direct channel targeting (Nassini et al., 1

DOI: 10.3390/nu10101537

The condition typically progresses through stages, beginning with simple steatosis (fat accumulation alone), potentially advancing to non-alcoholic steatohepatitis (NASH) where inflammation develops, and in some cases progressing to fibrosis, cirrhosis, or hepatocellular carcinoma

Beutler, 1975) and is reported as micromoles per gram of haemoglobin (mol/gHb)